Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the pharmaceutical industry with its innovative abuse-deterrent drug delivery system. The company’s AVERSA technology is at the heart of its development pipeline, featuring two key candidates: AVERSA Fentanyl and AVERSA Buprenorphine. These products are designed to combat the abuse and misuse of transdermal patches, a growing concern in public health.

The AVERSA Fentanyl patch, potentially the first of its kind, is projected to achieve peak annual U.S. sales between $80 and $200 million. Similarly, AVERSA Buprenorphine is expected to reach peak U.S. sales of $70 to $130 million upon approval. Both candidates leverage Nutriband’s scalable platform, which is on track for global patent protection, marking a significant milestone in the fight against drug abuse.

This development is crucial as it addresses the urgent need for safer drug delivery systems that minimize the risk of abuse, misuse, and accidental exposure. Nutriband’s efforts could set a new standard in the pharmaceutical industry, offering hope for reducing the opioid crisis’s impact. For more information, visit https://ibn.fm/8PgtJ.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Nutriband Inc. Advances Abuse-Deterrent Drug Delivery with AVERSA Technology.